Is Addyi (flibanserin) taken daily for a premenopausal woman with hypoactive sexual desire disorder?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Yes, Addyi (flibanserin) is a daily pill taken once nightly at bedtime.

Addyi must be taken as 100 mg once daily at bedtime—this is the FDA-approved dosing regimen for premenopausal women with hypoactive sexual desire disorder (HSDD). 1

Dosing Schedule

The medication is specifically dosed at bedtime (not during waking hours) because daytime administration significantly increases the risks of:

  • Hypotension
  • Syncope
  • Accidental injury
  • Central nervous system (CNS) depression 1

Patients must take this medication every night at bedtime for continuous treatment—it is not an "on-demand" medication taken before sexual activity. This distinguishes flibanserin from other sexual dysfunction treatments.

Key Clinical Considerations

Timeline for Effect

  • Discontinue treatment after 8 weeks if no improvement is observed 1
  • Clinical trials showed mean increases of approximately 1 additional satisfying sexual event every 2 months 2
  • Improvements in sexual desire (measured by FSFI desire domain scores) and reductions in distress were statistically significant but modest 3, 4, 5, 6

Critical Safety Requirements

Alcohol interaction is the most important counseling point:

  • Patients must wait at least 2 hours after consuming 1-2 standard alcoholic drinks before taking their bedtime dose
  • If 3 or more drinks consumed that evening, skip the dose entirely
  • Avoid alcohol until the following day after taking the bedtime dose 1

Activities requiring alertness:

  • Avoid operating machinery or driving for at least 6 hours after each dose and until the patient knows how the medication affects them 1
  • Common CNS effects include somnolence (8-12%), dizziness (10-11%), and fatigue (10%) 3, 4, 5

Contraindications (Absolute)

The medication is contraindicated in:

  • Patients taking moderate or strong CYP3A4 inhibitors
  • Patients with hepatic impairment of any degree 1

Drug Interactions to Monitor

  • Oral contraceptives and weak CYP3A4 inhibitors increase flibanserin exposure and adverse event rates 1
  • Strong CYP2C19 inhibitors increase exposure, raising hypotension/syncope risk 1
  • Digoxin levels increase—monitor digoxin concentrations more frequently 1
  • CYP3A4 inducers substantially reduce flibanserin concentrations; use not recommended 1

Evidence Quality Note

While flibanserin is FDA-approved and supported by multiple randomized controlled trials 3, 4, 5, 6, the clinical benefit is modest. The NCCN 2024 guidelines note it results in "approximately 1 additional satisfying sexual event every 2 months" 2. The ASCO 2018 guidelines specifically state "the risk/benefit ratio for this medication is uncertain" and note it has not been evaluated in women with cancer history or those on endocrine therapy 7.

The medication requires long-term daily commitment (potentially years in premenopausal women) with strict adherence to alcohol restrictions and bedtime dosing to minimize safety risks while achieving modest improvements in sexual desire and distress.

Related Questions

What 5‑HT2A antagonists are appropriate for a premenopausal woman with acquired generalized hypoactive sexual desire disorder, and what are their dosing and safety considerations?
How do bremelanotide and flibanserin affect sexual desire in premenopausal women with hypoactive sexual desire disorder, and what outcome measures (Female Sexual Function Index desire domain, Female Sexual Distress Scale, and number of satisfying sexual events) are used to assess their efficacy?
What are the indications, dosing regimen, contraindications, adverse effects, and counseling considerations for flibanserin in premenopausal women with acquired generalized hypoactive sexual desire disorder?
In a premenopausal woman treated for hypoactive sexual desire disorder, does flibanserin (Addyi) need to be tapered before discontinuation?
What FDA-approved medications are available to treat female sexual dysfunction, specifically hypoactive sexual desire disorder (HSDD)?
In a 30-year-old female with one-week facial, chest, and throat pressure, tachycardia, hypertension, no fever, cough, dyspnea, and no risk factors for thrombosis, what urgent evaluation and management is indicated?
What is the appropriate IV unfractionated heparin dosing regimen for an 86‑year‑old patient with non‑ST‑elevation myocardial infarction (NSTEMI)?
How should I manage a patient who refuses Lantus (insulin glargine)?
For how many weeks should a cast be worn for a simple arm fracture?
What are the appropriate heparin stat (initial) dosing recommendations for an 86‑year‑old patient with NSTEMI?
What standard probiotic should be prescribed for an adult patient without contraindications?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.